63 filings
Page 2 of 4
6-K
us0jw9qrlolsa0cxxh
28 Mar 23
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
8:00am
6-K
bzv48cjr8ctepp85
12 Jan 23
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
4:30pm
6-K
imo33y1mvzlxp7ar2
10 Nov 22
Current report (foreign)
8:30am
6-K
27471em ye
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
cel0ps5
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
oxbq 4gc5m15sc9e
16 Aug 22
Current report (foreign)
4:43pm
6-K
lpsrfuz0m3tms4
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am
6-K
7vum4mav5oi83 1j
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
y0v x0s8owg
14 Jun 22
Current report (foreign)
5:20pm
6-K
r8mnr9i rbpyk
16 May 22
Current report (foreign)
8:31am
6-K
ua8mj1
16 May 22
Silence Therapeutics plc Notice of Annual General Meeting
8:30am
6-K
xn1 biowzchki7tainf
25 Apr 22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
8:31am
6-K
hm55kh0klpa7m
4 Apr 22
Current report (foreign)
8:31am
6-K
bcy03dr82lpc ltu7awj
23 Mar 22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
8:30am
6-K
is89wdm6c slz8z
22 Feb 22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
6:52am
6-K
cywqzk tsxen2wzod
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
qe45lw
13 Dec 21
Current report (foreign)
6:01am
6-K
bv6 s70zcxgym3lmy
26 Nov 21
Current report (foreign)
6:23am
6-K
8kqb5t3
16 Nov 21
Current report (foreign)
6:03am
6-K
a4yuzusa
1 Nov 21
Results of General Meeting
5:30pm